Coenzyme Q10 in Older Athletes Treated With Statin Medications

A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Coenzyme Q10 in Improving Mitochondrial Function in Older Athletes Treated With Statin Medications

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01026311

Enrollment

Registered

2009-12-04

Start date

2009-11-30

Completion date

2011-03-31

Last updated

2012-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Weakness, Myalgia, Side Effects of Statins

Keywords

Coenzyme q10, statins, myalgias, anaerobic threshold, athletic performance

Brief summary

The purpose of this study is to evaluate the effect of coenzyme Q10 administration in improving mitochondrial function as measured by anaerobic threshold in older athletes on a stable dose of statin medication.

Interventions

DRUGCoenzyme q 10

200 mg of Coenzyme q 10

DRUGplacebo

1 placebo q d during treatment period

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients ≥ 50 years of age, male or female. * Patients on a stable dose of statin medication for at least 3 months prior to enrollment in the study * Self-Described Athletes with any of the following characteristics: * Participation in a competitive athletic event within the past year or currently training for a competitive athletic event within the 6 months following enrollment * Regular exercise activity of at least 45 minutes duration 5 times per week

Exclusion criteria

* Use of coenzyme Q10 during the preceding two months. * CPK level at baseline greater than two times the upper limits of normal * LDL level at baseline greater than 160 for those without a cardiovascular risk or cardiovascular risk equivalent * LDL level at baseline greater than 130 for those with a cardiovascular risk or cardiovascular risk equivalent

Design outcomes

Primary

Measure	Time frame
The primary objective of this study is to test if oral coenzyme Q10 is superior to placebo in improving oxygen consumption by mitochondria as measured by cardiopulmonary fitness testing for anaerobic threshold in this population	The study will consist of an initial six week treatment period followed by a six week washout period. Subjects will then crossover to the alternative treatment for a second six week study period.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026